- Home
- AVNT vs RYTM Comparison
AVNT vs RYTM Comparison
Compare AVNT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVNT
- RYTM
- Stock Information
- Founded
- AVNT 1927
- RYTM 2008
- Country
- AVNT United States
- RYTM United States
- Employees
- AVNT N/A
- RYTM N/A
- Industry
- AVNT Major Chemicals
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- AVNT Industrials
- RYTM Health Care
- Exchange
- AVNT Nasdaq
- RYTM Nasdaq
- Market Cap
- AVNT 3.4B
- RYTM 3.2B
- IPO Year
- AVNT 1993
- RYTM 2017
- Fundamental
- Price
- AVNT $30.64
- RYTM $46.39
- Analyst Decision
- AVNT Strong Buy
- RYTM Strong Buy
- Analyst Count
- AVNT 5
- RYTM 12
- Target Price
- AVNT $54.40
- RYTM $68.58
- AVG Volume (30 Days)
- AVNT 667.9K
- RYTM 543.7K
- Earning Date
- AVNT 05-06-2025
- RYTM 05-06-2025
- Dividend Yield
- AVNT 3.30%
- RYTM N/A
- EPS Growth
- AVNT 121.98
- RYTM N/A
- EPS
- AVNT 1.84
- RYTM N/A
- Revenue
- AVNT $3,240,400,000.00
- RYTM $130,126,000.00
- Revenue This Year
- AVNT $3.54
- RYTM $45.46
- Revenue Next Year
- AVNT $4.50
- RYTM $63.04
- P/E Ratio
- AVNT $20.58
- RYTM N/A
- Revenue Growth
- AVNT 3.11
- RYTM 68.06
- 52 Week Low
- AVNT $32.48
- RYTM $35.17
- 52 Week High
- AVNT $54.68
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- AVNT 24.46
- RYTM 39.41
- Support Level
- AVNT $36.01
- RYTM $48.23
- Resistance Level
- AVNT $37.97
- RYTM $54.67
- Average True Range (ATR)
- AVNT 1.28
- RYTM 2.42
- MACD
- AVNT -0.47
- RYTM -0.28
- Stochastic Oscillator
- AVNT 0.29
- RYTM 9.06
About AVNT Avient Corporation
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.